TRAXFirst Tracks Biotherapeutics, Inc.vs its industry peers
A metric-by-metric comparison of First Tracks Biotherapeutics, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TRAX본 종목 | $1.5B#2 | — | 6.0x#5 | — | — | — | — | 0.0%#2 | — | — | — | — |
| INVA | $1.5B#1 | 3.3x#1 | 1.2x#2 | 3.8x#2 | 14.7%#3 | — | 39.8%#1 | 0.0%#2 | 13.6%#2 | — | — | — |
| PRGO | $1.4B#3 | — | 0.6x#1 | 0.3x#1 | -2.8%#4 | -729.7%#5 | -26.4%#4 | -57.0%#6 | -19.7%#4 | 4#1 | — | 11.4%#1 |
| XERS | $1.4B#4 | 115.4x#2 | 107.2x#7 | 4.8x#3 | 43.7%#2 | 101.0%#1 | 8.5%#2 | 4.3%#1 | 20.3%#1 | — | — | — |
| MLTX | $1.4B#6 | — | 5.3x#4 | — | — | -91.1%#3 | — | -89.5%#7 | -448.8%#5 | — | — | — |
| AVBP | $1.4B#5 | — | 4.3x#3 | — | — | -106.6%#4 | — | -51.3%#5 | — | — | — | — |
| AVLN | $1.3B#7 | — | — | — | — | — | — | — | — | — | — | — |
| ETON | $1.3B#8 | — | 41.5x#6 | 15.9x#4 | 104.9%#1 | -20.4%#2 | -1.1%#3 | -15.0%#4 | -2.0%#3 | 4#1 | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-08-03.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice